API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TTX-030, a first-in-class, anti-CD39 antibody, inhibits the activity of CD39, an enzyme that converts ATP to AMP, the initial steps in the generation of adenosine in the tumor microenvironment.
Lead Product(s): Ttx-030,Docetaxel,Budigalimab
Therapeutic Area: Oncology Product Name: TTX-030
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
The Trishula launch is the result of the spin out of the TTX-030 program from Tizona Therapeutics with funds and employees to support its development.
Lead Product(s): Ttx-030,Budigalimab,Oxaliplatin
Therapeutic Area: Oncology Product Name: TTX-030
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020